Clinical advances and challenges associated with TCR-T cell therapy for cancer treatment
- Front Immunol. 2024 Oct 8:15:1487782. doi: 10.3389/fimmu.2024.1487782.
- 1. Heilongjiang University of Chinese Medicine, Harbin, China.
- 2. School of Mechanical and Electrical Engineering, Harbin Institute of Technology, Harbin, China.
- 3. Brandeis University, Waltham, MA, United States.
- 4. First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China.
Background: T cell receptor (TCR)-T cell therapy is an innovative form of Cancer Immunotherapy that genetically modifies patients' T cells to target and destroy Cancer cells. However, the current status of clinical trials of TCR-T cell therapy for the treatment of Cancer remains unclear. This study aimed to comprehensively analyze the registration trials related to TCR-T cell therapy for the treatment of Cancer.
Methods: A comprehensive search was conducted in the Trialtrove database for all clinical trials related to TCR-T cell therapy registered by August 1, 2024. Inclusion criteria focused on trials targeting TCR-T cell therapy for oncology, and excluded observational studies and incomplete data. Statistical analysis was performed on key trial characteristics, with between-group comparisons utilizing chi-square or Fisher's exact tests.
Results: Analysis of 174 eligible clinical trials revealed that TCR-T cell therapy exhibits significant efficacy across various tumor types, particularly in refractory hematologic malignancies and certain solid Tumors. Additionally, combining TCR-T cell therapy with other immunotherapies enhanced these anti-tumor effects.
Conclusion: TCR-T cell therapy holds substantial promise for Cancer treatment. Future research should focus on optimizing treatment protocols, enhancing efficacy, and minimizing prices to fully realize the potential of this therapy.